When tumors had reached an average volume of 50 mm3 (day = 0) mice were randomized into three groups (n = 5) receiving either a daily intratumoral dose of 2×1010 vp ICOVIR5-TK-L per tumor on days 0, 1, 7 and 8 followed by a daily dose of 100 mg/kg GCV intraperitoneally (i.p) on days 4, 5, 6, 11, 12 and 13; or Adwt-RGD instead of ICOVIR5-TK-L. Here, TKT is linked to neoplasm.